$655 Million is the total value of Darwin Global Management, Ltd.'s 13 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
AVTE | Exit | AEROVATE THERAPEUTICS INC | $0 | – | -12,484 | -100.0% | -0.05% | – |
Exit | ADAGIO THERAPEUTICS INC | $0 | – | -86,528 | -100.0% | -0.67% | – | |
BBIO | Exit | BRIDGEBIO PHARMA INC | $0 | – | -253,692 | -100.0% | -2.19% | – |
XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -2,000,000 | -100.0% | -63.36% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
FATE THERAPEUTICS INC | 5 | Q4 2021 | 24.2% |
KEROS THERAPEUTICS INC | 5 | Q1 2023 | 12.8% |
INHIBRX INC | 5 | Q4 2021 | 3.9% |
ACCELERON PHARMA INC | 4 | Q3 2021 | 63.4% |
AMBRX BIOPHARMA INC | 4 | Q3 2023 | 67.5% |
ARGENX SE | 4 | Q3 2023 | 70.2% |
BRIDGEBIO PHARMA INC | 4 | Q3 2021 | 25.2% |
FULCRUM THERAPEUTICS INC | 4 | Q4 2021 | 0.9% |
ASTRAZENECA PLC | 3 | Q2 2022 | 100.0% |
INTELLIA THERAPEUTICS INC | 3 | Q4 2021 | 48.6% |
View Darwin Global Management, Ltd.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
4 | 2023-06-28 |
SC 13D/A | 2023-06-28 |
SC 13D/A | 2023-05-25 |
13F-HR | 2023-05-15 |
SC 13G | 2023-04-03 |
3 | 2023-03-08 |
View Darwin Global Management, Ltd.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.